USP7 and cancer: C9, a quinazolin‐4‐one derivative synthesized by Li and collaborators, exhibited a low micromolar potency for inhibiting USP7 catalytic activity, thus decreasing MDM2 protein level and stabilizing p53 in cancer cells.